





To the Editor: Global surveillance
of drug resistance has shown that a
substantial proportion of tuberculosis
(TB) patients are infected with drug-
resistant Mycobacterium tuberculosis
strains (1). Earlier hospital-based sur-
veys have been undertaken in Taiwan,
but these lacked systematic sampling
and testing methods, which made
interpreting results difficult. The com-
bined treatment efficiency and the
actual prevalence of drug resistance
were unknown. Thus the Taiwan
Center for Disease Control initiated
the Taiwan Surveillance of Drug
Resistance in Tuberculosis program in
2002.
A laboratory surveillance system
was established and supervised by the
national reference laboratory. The
system includes 6 medical centers, 2
TB referral centers, and 1 regional
hospital, distributed in 4 regions of
Taiwan. The 9 laboratories provide
services for healthcare facilities in
their own and surrounding areas. Both
the national reference laboratory and
contract laboratories participated in
an external quality proficiency test
provided by the College of American
Pathologists and the national refer-
ence laboratory. Performance was
also assessed by the supranational ref-
erence laboratory in Antwerp,
Belgium.
The population in the first year
(2003) of the survey was 22,562,663,
the number of confirmed TB cases
was 15,042, the estimated incidence
was 66.7 per 100,000 population, and
the rate of notification of new positive
sputum samples was 34.6% (2). A
total of 3,699 isolates, ≈50% of M.
tuberculosis strains isolated, under-
went antimicrobial drug susceptibility
testing in the system. Since clinical
data were not available, only com-
bined (primary plus acquired) drug
resistance rates were analyzed. The
survey showed that the combined
drug resistance rates were 9.5% to
isoniazid, 5.8% to ethambutol, 6.4%
to rifampin, 9.6% to streptomycin,
20.0% to any drug, and 4.0% to mul-
tiple drugs. Resistance to any single
drug was 12.3%, to any 2 drugs was
4.8%, to any 3 drugs was 2.2%, and to
any 4 drugs was 0.7%. In the third
global drug resistance surveillance
report, the median prevalence of com-
bined drug resistance was 6.6% to iso-
niazid, 1.3% to ethambutol, 2.2% to
rifampin, 6.1% to streptomycin,
10.4% to any drug, and 1.7% to mul-
tiple drugs (1).
Available historical data from
Taiwan are not directly comparable
because of different sampling meth-
ods and because susceptibility testing
methods have been applied in various
hospital settings over time (Table,
available online at http://www.cdc.
gov/ncidod/EID/vol12no05/05-
1688.htm#table), which limits our
ability to monitor trends. The latest
drug resistance rates obtained from
Chest Hospital, a specialized TB
referral hospital, showed that the
combined drug resistance of any and
multiple drugs were 27.6% and
15.8%, respectively, from January
2002 to June 2004 (unpub. data).
In Taiwan, isoniazid and rifampin
were introduced in 1957 and 1978,
respectively. Rifampin resistance was
first seen in Taiwan in 1982. In recent
decades, however, the rates of pri-
mary rifampin resistance have
increased (online Table), and primary
resistance to multiple drugs has
increased to 2.4% over time.
Based on patient data collected
from Chest Hospital, multidrug resist-
ance occurred in 42.2% of retreated
TB patients, and 1.8% of multidrug-
resistant isolates were found in new
TB patients from January 2002 to
June 2004 (unpub. data). In the third
global drug resistance surveillance
report, the median prevalence of mul-
tidrug resistance was 7.0% (highest
58.3%) among retreated cases and
1.1% (highest 14.2%) among new
cases.
Significant declining trends were
observed for any acquired resistance
(67.0% to 42.6%, p<0.0001) and
acquired multidrug resistance (46.0%
to 24.6%, p<0.0001) at the Taiwan
Provincial Chronic Disease Control
Bureau from 1996 to 2001 (3,4). In
addition, a decline in combined isoni-
azid resistance (43.1% to 16.4%,
p<0.0001), rifampin resistance
(23.4% to 9.5%, p<0.0049), and mul-
tidrug resistance (18.2% to 7.8%,
p<0.0113) was also reported from
Kaohsiung Medical University
Hospital from 1996 to 2000 (5). Taken
together, data obtained from the
Taiwan Surveillance of Drug
Resistance in Tuberculosis and those
reported previously show that rates of
combined resistance to any drugs and
multiple drugs has declined in
Taiwan.
For retreated cases, the high
acquired resistance rates indicated
suboptimal initial treatment and insuf-
ficient case management of new
patients, which raises a challenge to
the National TB Control Programme
in Taiwan. The direct observed treat-
ment, short-course (DOTS) strategy
has consequently been suggested to
expand to all patients with newly
diagnosed cases. The Taiwan
Surveillance of Drug Resistance in
Tuberculosis program will be extend-
ed to collect each patient’s clinical
and epidemiologic data, according to
principles suggested in the guidelines
prepared by the World Health
Organization.
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To the Editor: Following logic
similar to that recently used by the US
Food and Drug Administration to
withdraw approval for enrofloxacin, a
recent letter estimated that fluoro-
quinolone use in poultry could com-
promise responses to antimicrobial
drugs in >24,000 persons per year in
the United States (1). However,
>99.9% of this estimated risk appears
to result from incorrect assumptions.
Potentially important corrections
include the following: 1) not attribut-
ing resistance from foreign travel and
human ciprofloxacin use to domestic
use of enrofloxacin in poultry (this
could reduce the estimated risk by
≈1/3) (2); 2) updating the estimated
fraction of human foodborne
Campylobacter infections caused by
poultry to reflect declines in microbial
loads on chicken carcasses since 1992
reduces the estimated risk by a factor
of perhaps 1/10 (3) (the cited 90%
estimate by Hurd et al. [1] was intend-
ed for use as part of a conservative
upper-bounding analysis, not as a
realistic point estimate); 3) replacing
an assumption that 10% of infected
persons would benefit from antimi-
crobial drug therapy with a more data-
based value of 0.6% (4) would
reduces the estimated risk by a factor
of 0.6/10 = 0.06; 4) replacing an
assumption that fluoroquinolones are
prescribed for all affected patients
receiving antimicrobial drug treat-
ment (rather than, for example, eryth-
romycin) by a more realistic value of
fluoroquinolones being prescribed for
perhaps ≈50% of patients (2) reduces
the estimated risk by a factor of
≈50%; 5) replacing an assumption
that all such cases lead to compro-
mised responses with a more data-
driven estimate that perhaps ≈17% of
patients have compromised responses
would reduce the estimated risk by a
factor of 1/6 (5); and 6) recognizing
that reducing enrofloxacin use may
not decrease fluoroquinolone resist-
ance in all Campylobacter spp. from
food animals (effect not quantified)
(6). Together, such changes reduce the
estimated risk by a factor of at least
(1/3) × (1/10) × (0.6/10) × (1/2) ×
(1/6) = 0.00017, or by >99.9%. 
More notably, the calculation in
(1) also wrongly assumes that the
fraction of patients with fluoro-
quinolone-resistant infections times
the fraction of infections caused by
poultry gives the fraction of patients
with compromised response caused
by fluoroquinolone use in poultry. As
a simple counterexample, suppose
that 80% of all infections were caused
by poultry, with the rest caused by
something else (e.g., water), and that
all and only the 20% of infections
caused by the latter source are resist-
ant. Then the procedure in (1) would
estimate (80% of infections caused by
poultry) × (20% of infections resist-
ant) = 16% as the fraction of resistant
infections caused by poultry, even
though the correct answer is zero.
Thus, the basic logic of the calcula-
tion is flawed. 
Louis Anthony Cox, Jr*†
*Cox Associates, Denver, Colorado, USA;
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Sciences Center, Denver, Colorado, USA
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